Neoantigen-targeted CD8⁺ T cell responses with PD-1 blockade therapy.

ABSTRACT: Neoantigens are peptides derived from non-synonymous mutations presented by human leukocyte antigens (HLAs), which are recognized by antitumour T cells^1-14. The large HLA allele diversity and limiting clinical samples have restricted the study of the landscape of neoantigen-targeted T cell responses in patients over their treatment course. Here we applied recently developed technologies^15-17 to capture neoantigen-specific T cells from blood and tumours from patients with metastatic melanoma with or without response to anti-programmed death receptor 1 (PD-1) immunotherapy. We generated personalized libraries of neoantigen-HLA capture reagents to single-cell isolate the T cells and clone their T cell receptors (neoTCRs). Multiple T cells with different neoTCR sequences

SUBMITTER: Puig-Saus C 

PROVIDER: S-EPMC10441586 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature